Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer

被引：55

作者：

Bouchahda, M. ^{[1
]}

Macarulla, T. ^{[2
]}

Spano, J. P. ^{[3
]}

Bachet, J. B. ^{[4
]}

Lledo, G. ^{[5
]}

Andre, T. ^{[6
]}

Landi, B. ^{[7
]}

Tabernero, J. ^{[2
]}

Karaboue, A.

Domont, J. ^{[3
]}

Levi, F.

Rougier, P. ^{[4
]}

机构：

[1] Hop Paul Brousse, Med Oncol Serv, F-94800 Villejuif, France

[2] Valle Hebron Univ Hosp, Barcelona, Spain

[3] Hop La Pitie Salpetriere, Paris, France

[4] Hop Ambroise Pare, Paris, France

[5] Clin St Jean, Lyon, France

[6] Hop Tenon, F-75970 Paris, France

[7] Hop Europeen Georges Pompidou, Paris, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2008年 / 67卷 / 03期

关键词：

cetuximab; chemotherapy; colorectal cancer; elderly;

D O I：

10.1016/j.critrevonc.2008.02.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Few data are available from clinical trials for elderly patients receiving cetuximab. Patients and methods: The clinical data of consecutive patients aged >= 70 years given cetuximab for metastatic CRC were retrospectively captured from hospital pharmacy registries in seven centers. Results: Fifty-six patients received cetuximab with irinotecan. Median age was 76 years (70-84), 86% of patients were pretreated with fluoropyrimidines, irinotecan and oxaliplatin and 69.6% had documented resistance to irinotecan. Objective response rate was 21% (95% CI: 11-32%). The median progression-free survival was 4.4 months (95% Cl: 3.0-5.7 months) and the median overall survival was 16.0 months (95% CI: 13.5-18.5 months). Skin rash occurred in 75% of the patients (11% grade 3) and diarrhea in 80% (20% grades 3-4). Conclusion: Tolerability of cetuximab was acceptable in elderly patients with pretreated metastatic CRC. Efficacy appeared similar to that observed in younger patients. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：255 / 262

页数：8

共 50 条

[21] Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC) [J].

S. Abdelwahab ;

A. Azmy ;

H. Abdel-aziz ;

H. Salim ;

A. Mahmoud .

Journal of Cancer Research and Clinical Oncology, 2012, 138 :1487-1492

[22] Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC) [J].

Abdelwahab, S. ;

Azmy, A. ;

Abdel-aziz, H. ;

Salim, H. ;

Mahmoud, A. .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (09) :1487-1492

[23] Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer [J].

Sabatier, Renaud ;

Martin, Johan ;

Vicier, Cecile ;

Guerin, Mathilde ;

Monneur, Audrey ;

Provansal, Magali ;

Tassy, Louis ;

Tarpin, Carole ;

Extra, Jean-Marc ;

Viret, Frederic ;

Goncalves, Anthony .

JOURNAL OF CLINICAL MEDICINE, 2021, 10 (06) :1-10

[24] Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer [J].

Osako, Tomo ;

Ito, Yoshinori ;

Ushijima, Masaru ;

Takahashi, Shunji ;

Tokudome, Nahomi ;

Sugihara, Tsutomu ;

Iwase, Takuji ;

Matsuura, Masaaki ;

Hatake, Kiyohiko .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (05) :865-871

[25] Efficacy and Safety of Ixabepilone Monotherapy and Ixabepilone-Capecitabine Combination in Patients with Heavily Pretreated Metastatic Breast Cancer [J].

Sarici, Furkan ;

Aksoy, Serean .

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2021, 31 (02) :85-91

[26] Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer [J].

Rosati, Gerardo ;

Addeo, Raffaele ;

Aprile, Giuseppe ;

Avallone, Antonio ;

Bilancia, Domenico ;

Brugnatelli, Silvia ;

Buccafusca, Gabriella ;

Carlomagno, Chiara ;

Cordio, Stefano ;

Delfanti, Sara ;

Dell'Aquila, Emanuela ;

Di Bisceglie, Maurizio ;

Di Donato, Samantha ;

Di Stasi, Antonio ;

Germano, Domenico ;

Giuliani, Francesco ;

Granetto, Cristina ;

Latiano, Tiziana Pia ;

Leo, Silvana ;

Tralongo, Paolo ;

Stroppolo, Maria Elena ;

Venturini, Filippo ;

Bianco, Salvatore .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (05) :1089-1096

[27] Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer [J].

Mizota, Ayako ;

Shitara, Kohei ;

Kondo, Chihiro ;

Nomura, Motoo ;

Yokota, Tomoya ;

Takahari, Daisuke ;

Ura, Takashi ;

Inaba, Yoshitaka ;

Yamaura, Hidekazu ;

Sato, Yozo ;

Kato, Mina ;

Muro, Kei .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (04) :416-420

[28] Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer [J].

Ayako Mizota ;

Kohei Shitara ;

Chihiro Kondo ;

Motoo Nomura ;

Tomoya Yokota ;

Daisuke Takahari ;

Takashi Ura ;

Yoshitaka Inaba ;

Hidekazu Yamaura ;

Yozo Sato ;

Mina Kato ;

Kei Muro .

International Journal of Clinical Oncology, 2011, 16

[29] Bevacizumab in elderly patients with metastatic colorectal cancer [J].

Sclafani, Francesco ;

Cunningham, David .

JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (01) :78-88

[30] Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study [J].

Pedersini, Rebecca ;

Vassalli, Lucia ;

Claps, Melanie ;

Tulla, Antonella ;

Rodella, Filippo ;

Grisanti, Salvatore ;

Amoroso, Vito ;

Roca, Elisa ;

Simoncini, Edda Lucia ;

Berruti, Alfredo .

ONCOLOGY, 2018, 94 :10-15

← 1 2 3 4 5 →